Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)
Abstract Background SGLT2 inhibitors represent a revolutionary drug class that delivers benefits exceeding those of diabetes management alone. Initially approved for type 2 diabetes management, research continually demonstrates their protective effects on kidney function across several nephrological...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2025-06-01
|
| Seri Bilgileri: | Diabetology & Metabolic Syndrome |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s13098-025-01790-w |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|